Clinics in Dermatology
Volume 26, Issue 5 , Pages 503-508 , September 2008

Alefacept in the treatment of psoriasis

References 

  1. Wrone-Smith T, Nickoloff BJ. Dermal injection of immunocytes induces psoriasis. J Clin Invest. 1996;98:1878–1887
  2. Nickoloff BJ, Bonish B, Huang BB, et al. Characterization of a T cell line bearing natural killer receptors and capable of creating psoriasis in a SCID mouse model system. J Dermatol Sci. 2000;24:212–225
  3. Boyman O, Hefti HP, Conrad C, et al. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. J Exp Med. 2004;199:731–736
  4. Sugiyama H, Gyulai R, Toichi E, et al. Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol. 2005;174:164–173
  5. Ellis CN, Gorsulowsky DC, Hamilton TA, et al. Cyclosporine improves psoriasis in a double-blind study. JAMA. 1986;256:3110–3116
  6. Weinstein GD, Jeffes E, McCullough JL. Cytotoxic and immunologic effects of methotrexate in psoriasis. J Invest Dermatol. 1990;95(5 Suppl):49S–52S
  7. Waters CA, Snider CE, Itoh K, et al. DAB486IL-2 (IL-2 toxin) selectively inactivates high-affinity IL-2 receptor–bearing human peripheral blood mononuclear cells. Ann N Y Acad Sci. 1991;636:403–405
  8. Gottlieb SL, Gilleaudeau P, Johnson R, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995;1:442–447
  9. Brottier P, Boumsell L, Gelin C, et al. T cell activation via CD2 [T, gp50] molecules: accessory cells are required to trigger T cell activation via CD2-D66 plus CD2-9.6/T11(1) epitopes. J Immunol. 1985;135:1624–1631
  10. June CH, Fletcher MC, Ledbetter JA, et al. Increases in tyrosine phosphorylation are detectable before phospholipase C activation after T cell receptor stimulation. J Immunol. 1990;144:1591–1599
  11. Danielian S, Fagard R, Alcover A, et al. The tyrosine kinase activity of p56lck is increased in human T cells activated via CD2. Eur J Immunol. 1991;21:1967–1970
  12. Majeau GR, Meier W, Jimmo B, et al. Mechanism of lymphocyte function–associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure/function analysis in vitro and in human CD2 transgenic mice. J Immunol. 1994;152:2753–2767
  13. Kaplon RJ, Hochman PS, Michler RE, et al. Short course single agent therapy with an LFA-3-IgG1 fusion protein prolongs primate cardiac allograft survival. Transplantation. 1996;61:356–363
  14. Miller GT, Hochman PS, Meier W, et al. Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses. J Exp Med. 1993;178:211–222
  15. Bos JD, Hagenaars C, Das PK, et al. Predominance of “memory” T cells (CD4+, CDw29+) over “naive” T cells (CD4+, CD45R+) in both normal and diseased human skin. Arch Dermatol Res. 1989;281:24–30
  16. Morganroth GS, Chan LS, Weinstein GD, et al. Proliferating cells in psoriatic dermis are comprised primarily of T cells, endothelial cells, and factor XIIIa+ perivascular dendritic cells. J Invest Dermatol. 1991;96:333–340
  17. Haider AS, Lowes MA, Gardner H, et al. Novel insight into the agonistic mechanism of alefacept in vivo: differentially expressed genes may serve as biomarkers of response in psoriasis patients. J Immunol. 2007;178:7442–7449
  18. Krueger GG, Papp KA, Stough DB, et al. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2002;47:821–833
  19. Krueger GG. Clinical response to alefacept: results of a phase 3 study of intravenous administration of alefacept in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2003;17(Suppl 2):17–24
  20. Gordon KB, Vaishnaw AK, O'Gorman J, et al. Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts. Arch Dermatol. 2003;139:1563–1570
  21. Feldman SR, Menter A, Koo JY. Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis. Br J Dermatol. 2004;150:317–326
  22. Lebwohl M, Christophers E, Langley R, et al. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol. 2003;139:719–727
  23. Ortonne JP. Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2003;17(Suppl 2):12–16
  24. Gordon KB, Langley RG. Remittive effects of intramuscular alefacept in psoriasis. J Drugs Dermatol. 2003;2:624–628
  25. Finlay AY, Salek MS, Haney J. Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis. Dermatology. 2003;206:307–315
  26. Ortonne JP, Lebwohl M, Em Griffiths C. Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis. Eur J Dermatol. 2003;13:117–123
  27. Gottlieb AB, Casale TB, Frankel E, et al. CD4+ T-cell–directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study. J Am Acad Dermatol. 2003;49:816–825
  28. Lowe NJ, Gonzalez J, Bagel J, et al. Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy. Int J Dermatol. 2003;42:224–230
  29. Biogen Idec . Amevive (Alefacept) briefing document. Dermatologic and Ophthalmic Drugs Advisory Committee Meeting. Available at: www.fda.gov/ohrms/dockets/ac/02/briefing/3865B1_01_Biogen.pdf[Internet; accessed January 26. 2005]
  30. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med. 2001;345:248–255

PII: S0738-081X(07)00251-9

doi: 10.1016/j.clindermatol.2007.10.028

Clinics in Dermatology
Volume 26, Issue 5 , Pages 503-508 , September 2008

Article Tools

* Image Usage & Resolution